ChromaDex Expands Distribution Of Niagen+ IV And Injections To 14 New Wellness Clinics; Wells Pharma To Compound And Distribute Pharmaceutical-Grade Niagen Following Successful Initial Launch
Portfolio Pulse from Benzinga Newsdesk
ChromaDex is expanding the distribution of its Niagen+ IV and injections to 14 new wellness clinics. Wells Pharma will compound and distribute pharmaceutical-grade Niagen following a successful initial launch.
September 10, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ChromaDex is expanding its distribution network for Niagen+ IV and injections to 14 new wellness clinics, with Wells Pharma handling compounding and distribution. This expansion follows a successful initial launch, indicating potential growth in market reach and revenue.
The expansion to 14 new clinics suggests increased market penetration and potential revenue growth for ChromaDex. The involvement of Wells Pharma in compounding and distribution further supports the scalability and reliability of the product's supply chain. This news is likely to positively impact ChromaDex's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100